Key Facts
• Kobayashi Pharmaceutical CEO Kaichi Toyoda, 60, aims to rebuild after health issues.
• Toyoda stated on June 3 that he will not cater to founding family opinions.
• Governance reforms include reducing reliance on the founding family in management.
• March shareholder meeting rejected proposal to appoint an external board chair.
• Current chair Yoshihito Ota, an external appointee, leads governance improvements.
• Founding family members Kazumasa Kobayashi and Akihiro Kobayashi retain roles.
• Toyoda values their expertise but asserts independence in decision-making.
• Compensation for health damage caused by red yeast rice supplements is prioritized.
Summary
Kobayashi Pharmaceutical CEO Kaichi Toyoda is leading efforts to recover from health issues linked to the company’s red yeast rice supplements. In a June 3 interview, Toyoda emphasized independence from the founding family, stating their opinions will not influence management decisions. Despite this, he supports their continued involvement, citing their valuable expertise. Governance reforms are underway, including appointing external chair Yoshihito Ota to strengthen oversight. A March proposal to formalize this role was rejected by the founding family. Toyoda assured that compensation for affected customers and partners remains a top priority.
